The Effect Of Curcumin On Some Of Traditional And Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial
Notes for this study:
||(mg/dl). Placebo: before 17.85±6.91, after 17.25±7.31. Curcumin: before 28.53±12.38, after 22.68±8.10
|Number of Subjects
||18-29, 30-44, 45-64, 65+
In a randomized, double-blind, placebo-controlled pilot trial, 40 coronary artery disease patients were assigned to take 2,000 mg of curcumin or placebo daily for 2 months. There were no statistically significant differences between groups for change in total cholesterol, LDL-C, HDL-C, VLDL, triglycerides, fasting glucose, hs-CRP, urea, or creatinine, However, while not statistically significant, LDL-c and VLDL-C, triglycerides, fasting glucose, and c-reactive protein were reduced in the curcumin group more than in the placebo group.